The U.S. Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at a rate of $2,989.55 per test, effective Jan. 1, 2026. The FDA‑approved comprehensive genomic profiling (CGP) assay interrogates >500 genes across DNA and RNA and is approved as a companion diagnostic for NTRK and RET fusion indications. Illumina framed the CMS decision as a removal of adoption barriers and expects broader clinical access to CGP in solid tumors. The change may accelerate clinical uptake of tissue‑based CGP by payers and providers.